Detail akcie Pacira Pharma online

Business Summary: Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company is engaged in advancing a pipeline of products across a range of therapeutic areas that include acute postsurgical pain; acute and chronic osteoarthritis (OA), pain, spasticity and stellate ganglion block. The Company is developing interventions to address debilitating conditions involving the sympathetic nervous system. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, Pacira Biosciences Inc revenues decreased less than 1% to $493.7M. Net income decreased 34% to $17.1M., also reflect Royalty revenue decrease of 46% to $1.3M. Net income was partially offset by Other Selling, general and administrat increase of 9% to $178.4M (expense), Acquisition-related charges (gains) and decrease of 91% to $1.2M (income), Stock based Compensation in R&D increase of 22% to $5.8M (expense).